| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 127, 549-558, Copyright © 1987 by American Society for Investigative Pathology
REGULAR ARTICLES |
HM Shulman, AM Gown and DJ Nugent
The authors immunostained autopsy liver tissue from 31 marrow transplant recipients, 19 with hepatic veno-occlusive disease (VOD) and 12 without VOD. A panel of monoclonal and polyclonal antibodies was used to characterize the materials within the occluded venous lesions and to define the location and types of injured cells. Most patients with early VOD (survival less than 50 days, n = 11) had dense periadventitial and intramural immunostaining of terminal hepatic and sublobular central venules (CV) with anti-Factor VIII (9/11) and anti- fibrinogen (4/4) but had no immunostaining with antibody to platelet GPIb. Early VOD patients also had marked loss of Zone 3 hepatocyte cytokeratin (8/9) versus late VOD (1/5) or non-VOD (2/7). Patients with late VOD lesions (n = 8, survival greater than 50 days) had increased collagen within occluded VOD lesions. Type III much greater than Type I, and increased sinusoidal collagens Types I, III, and IV. These studies and other data suggest the following events in the genesis of VOD. Initial injury to endothelium of CV and/or sinusoids and possibly also to Zone 3 hepatocytes triggers the coagulation cascade in the periadventitial zone of CV. The late sequela, collagenous CV occlusion, results from activated mural myofibroblasts and/or embolized Ito cells and hepatocytes.
This article has been cited by other articles:
 |
|
 |
|
  X. W. Huang, J. Yang, A. F. Dragovic, H. Zhang, T. S. Lawrence, and M. Zhang Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clin. Cancer Res., May 1, 2006; 12(9): 2849 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B Ibrahim, E. Peres, R. Dansey, M. H Abidi, E. M Abella, and J. Klein Anti-Thrombin III in the Management of Hematopoietic Stem-Cell Transplantation-Associated Toxicity Ann. Pharmacother., June 1, 2004; 38(6): 1053 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Richardson, C. Murakami, Z. Jin, D. Warren, P. Momtaz, D. Hoppensteadt, A. D. Elias, J. H. Antin, R. Soiffer, T. Spitzer, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome Blood, December 15, 2002; 100(13): 4337 - 4343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Richardson, A. D. Elias, A. Krishnan, C. Wheeler, R. Nath, D. Hoppensteadt, N. M. Kinchla, D. Neuberg, E. K. Waller, J. H. Antin, et al. Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population Blood, August 1, 1998; 92(3): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Salat, E. Holler, H.-J. Kolb, B. Reinhardt, R. Pihusch, W. Wilmanns, and E. Hiller Plasminogen Activator Inhibitor-1 Confirms the Diagnosis of Hepatic Veno-Occlusive Disease in Patients With Hyperbilirubinemia After Bone Marrow Transplantation Blood, March 15, 1997; 89(6): 2184 - 2188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Anscher, W. P. Peters, H. Reisenbichler, W. P. Petros, and R. L. Jirtle Transforming Growth Factor {beta} as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer N. Engl. J. Med., June 3, 1993; 328(22): 1592 - 1598. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
